European orphan medicinal product designation granted for [²¹²Pb]VMT-α-NET for the treatment of GEP-NETs [²¹²Pb]VMT-α-NET is being evaluated in an ongoing Phase 1/2a study in patients with SSTR2-positive...
SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...
SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...
One new responder observed in the [ 212 Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated...
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...
Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability Three clinical-stage oncology programs advancing across neuroendocrine...
Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...
Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...
Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...